Uploaded November 2026 | Updated November 2026, 3 days ago
GLP-1 weight loss drugs causing blindness…
Texans using GLP-1 drugs for weight loss or diabetes now face a new safety warning from the Food and Drug Administration about the risk of a rare eye condition that can cause permanent vision loss.
The FDA announced it will require all GLP-1 medications, including popular drugs like Ozempic, Wegovy, Mounjaro, Zepbound and Foundayo, to carry a warning about nonarteritic anterior ischemic optic neuropathy or NAION. NAION is caused by reduced blood flow to the optic nerve and can result in sudden, irreversible vision loss. The FDA decision follows a review of clinical trials, patient reports and published research, but the agency said a direct connection between the medications and NAION is still unclear. Cases have been reported for all marketed GLP-1 products.
Stephanie Colorado, an Austin optometrist, explained that NAION is "like a stroke of the eye where the blood vessels, pretty much the blood flow to the optic nerve, it starves your optic nerves."
She said symptoms can include waking up with blurry vision but described the risk as very low.
"The risk is still very low. So when the FDA did a meta-analysis, they basically took a group of people that were on GLP ones and said, maybe six out of 100,000 people can potentially have this disease," Colorado said.
Colorado, who has taken GLP-1 medications herself, is not worried but encourages being proactive.
"Go get an eye exam just to check your optic nerve and make sure you don't have what we call a disk at risk," she said.
GLP-1 weight loss drugs causing blindness…
Texans using GLP-1 drugs for weight loss or diabetes now face a new safety warning from the Food and Drug Administration about the risk of a rare eye condition that can cause permanent vision loss.
The FDA announced it will require all GLP-1 medications, including popular drugs like Ozempic, Wegovy, Mounjaro, Zepbound and Foundayo, to carry a warning about nonarteritic anterior ischemic optic neuropathy or NAION. NAION is caused by reduced blood flow to the optic nerve and can result in sudden, irreversible vision loss. The FDA decision follows a review of clinical trials, patient reports and published research, but the agency said a direct connection between the medications and NAION is still unclear. Cases have been reported for all marketed GLP-1 products.
Stephanie Colorado, an Austin optometrist, explained that NAION is "like a stroke of the eye where the blood vessels, pretty much the blood flow to the optic nerve, it starves your optic nerves."
She said symptoms can include waking up with blurry vision but described the risk as very low.
"The risk is still very low. So when the FDA did a meta-analysis, they basically took a group of people that were on GLP ones and said, maybe six out of 100,000 people can potentially have this disease," Colorado said.
Colorado, who has taken GLP-1 medications herself, is not worried but encourages being proactive.
"Go get an eye exam just to check your optic nerve and make sure you don't have what we call a disk at risk," she said.










